Abstract:Casein kinase 2 (CK2) is a highly pleiotropic serine-threonine kinase, which catalyzed phosphorylation of more than 300 proteins that are implicated in regulation of many cellular functions, such as signal transduction, transcriptional control, apoptosis and the cell cycle. On the other hand, CK2 is abnormally elevated in a variety of tumors, and is considered as a promising therapeutic target. The currently available ATP-competitive CK2 inhibitors, however, lack selectivity, which has impeded their development in cancer therapy. Because allosteric inhibitors can avoid the shortcomings of conventional kinase inhibitors, this study was aimed to discover a new allosteric site in CK2α and to investigate the effects of mutations in this site on the activity of CK2α. Using Allosite based on protein dynamics and structural alignment, we predicted a new allosteric site that was partly located in the αC helix of CK2α. Five residues exposed on the surface of this site were mutated to validate the prediction. Kinetic analyses were performed using a luminescent ADP detection assay by varying the concentrations of a peptide substrate, and the results showed that the mutations I78C and I78W decreased CK2α activity, whereas V31R, K75E, I82C and P109C increased CK2α activity. Potential allosteric pathways were identified using the Monte Carlo path generation approach, and the results of these predicted allosteric pathways were consistent with the mutation analysis. Multiple sequence alignments of CK2α with the other kinases in the family were conducted using the ClustalX method, which revealed the diversity of the residues in the site. In conclusion, we identified a new allosteric site in CK2α that can be altered to modulate the activity of the kinase. Because of the high diversity of the residues in the site, the site can be targeted using rational drug design of specific CK2α inhibitors for biological relevance.

Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases

Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.

Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments

New Promise and Opportunities for Allosteric Kinase Inhibitors

Novel Method to Identify Group-Specific Non-Catalytic Pockets of Human Kinome for Drug Design.

The Chemical Diversity and Structure-Based Discovery of Allosteric Modulators for the PIF-pocket of Protein Kinase PDK1

Dual Roles of ATP-binding Site in Protein Kinases: Orthosteric Inhibition and Allosteric Regulation.

Strategy toward Kinase-Selective Drug Discovery

Insights Into The Impact Of Linker Flexibility And Fragment Ionization On The Design Of Ck2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies

A novel allosteric site in casein kinase 2α discovered using combining bioinformatics and biochemistry methods

Rapid Identification of Inhibitors and Prediction of Ligand Selectivity for Multiple Proteins: Application to Protein Kinases

A Systematic Molecular and Pharmacologic Evaluation of AKT Inhibitors Reveals New Insight into Their Biological Activity

Latent allosteric control of protein interactions by ATP-competitive kinase inhibitors

Comprehensive Assessment of Nine Docking Programs on Type II Kinase Inhibitors: Prediction Accuracy of Sampling Power, Scoring Power and Screening Power.

Docking of Protein Kinase B Inhibitors: Implications in the Structure-Based Optimization of A Novel Scaffold

Prediction of Allosteric Druggable Pockets of Cyclin-Dependent Kinases

Designing of kinase hinge binders: A medicinal chemistry perspective

[Progress in the Design of Selective ATP-competitive Kinase Inhibitors].

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors

Structure-based drug design and molecular dynamics studies of an allosteric modulator targeting the protein–protein interaction site of PDK1